Royal Bank Of Canada Cuts argenex (NASDAQ:ARGX) Price Target to $890.00

argenex (NASDAQ:ARGX) had its target price dropped by research analysts at Royal Bank Of Canada from $925.00 to $890.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 15.07% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley increased their price target on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research report on Thursday, December 4th. DZ Bank upgraded shares of argenex to a “strong-buy” rating in a research note on Friday, December 19th. Stifel Nicolaus boosted their price objective on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Wedbush reaffirmed an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research report on Wednesday, January 14th. Finally, Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Stock Up 0.2%

ARGX traded up $1.88 on Friday, reaching $773.41. 278,985 shares of the company traded hands, compared to its average volume of 390,995. argenex has a one year low of $510.05 and a one year high of $934.62. The firm has a fifty day simple moving average of $828.13 and a two-hundred day simple moving average of $809.87. The company has a market cap of $47.86 billion, a P/E ratio of 33.21, a price-to-earnings-growth ratio of 0.71 and a beta of 0.37.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.05 by $1.97. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. On average, equities analysts forecast that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its stake in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC lifted its position in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth lifted its position in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares during the period. Geneos Wealth Management Inc. grew its stake in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of argenex by 27.1% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock valued at $1,066,000 after purchasing an additional 412 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx announced positive topline results from the Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis, meeting the primary endpoint (p=0.012) and supporting a planned sBLA submission — a clear catalyst for future label expansion and sales growth. ADAPT OCULUS Results
• Positive Sentiment: argenx reported strong Q4 and full‑year 2025 financials: $1.32B in Q4 product net sales (beat) and ~$4.2B for the year (≈90% YoY growth), and an EPS beat ($8.02 vs. $6.05 est.) — fundamentals that validate commercial traction for VYVGART and underpin higher valuation assumptions. Q4 Earnings Release
• Positive Sentiment: Citizens Jmp and HC Wainwright raised price targets (to $944 and $940, respectively) and kept bullish ratings, signaling continued analyst confidence in upside from current levels. Analyst Raises
• Neutral Sentiment: Robert W. Baird nudged its target slightly to $867 but maintained a neutral rating — a modest endorsement but less bullish than some peers. Baird Update
• Neutral Sentiment: Guggenheim and Wells Fargo trimmed their price targets (Guggenheim to $1,120; Wells Fargo to $1,247) but kept buy/overweight stances — indicates analysts are calibrating upside after earnings while still positive on the story. Analyst Cuts
• Neutral Sentiment: Reported short‑interest data in the filings looks anomalous (values shown as 0/NaN and days‑to‑cover 0.0), so short‑interest signals are unreliable in the current reporting — treat with caution.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.